#215 PCSK9 Inhibitors: Cardiovascular prevention panacea or pesky, pricey pokes?
CLINICAL QUESTION
Do pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors decrease cardiovascular events, and if so, are they cost-effective?
BOTTOM LINE
For patients with cardiovascular disease (CVD) already on maximally tolerated statins, adding evolocumab or alirocumab decreases new CVD events for an additional one in 65 patients compared to placebo over ~2.5 years. Routine use of these agents is not cost-effective at current prices.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- Focusing on two largest, industry-sponsored, placebo-controlled trials evaluating clinical outcomes.1,2 Patients had existing CVD and LDL >1.8 mmol/L while on maximally tolerated statins.1,2
- Evolocumab: 27,564 patients randomized to evolocumab (140 mg every two weeks or 420 mg monthly) or placebo.1 At 2.2 years:
- New CVD events: Evolocumab 9.8%, placebo 11.3%, statistically significant.
- Number Needed to Treat (NNT)=67.
- CVD reduction: Independent of baseline LDL.
- Death (any cause): No difference.
- New CVD events: Evolocumab 9.8%, placebo 11.3%, statistically significant.
- Alirocumab: (pending publication) 18,924 patients post-acute coronary syndrome randomized to alirocumab (75-150 mg every two weeks) or placebo.2 At 2.8 years statistically significant reduction in:
- New CVD events: Alirocumab 9.5%, placebo 11.1%, NNT=63.
- Death (any cause): Alirocumab 3.5%, placebo 4.1%, NNT=167.
- Note: Statistical difference in death based on six fewer deaths.
- Evolocumab: 27,564 patients randomized to evolocumab (140 mg every two weeks or 420 mg monthly) or placebo.1 At 2.2 years:
- Adverse events:1,2
- Primarily injection site reactions: Number Needed to Harm ~100.
- Other smaller randomized controlled trials limited by only reporting surrogate outcomes,3 lack of blinding,4,5 and enrolling familial hypercholesterolemia patients4 or patients from previous studies.3,5 These studies found inconsistent effects on CVD.5,6
- Bococizumab research and development stopped due to development of drug-neutralizing antibodies.7
- Development of neutralizing antibodies to alirocumab and evolocumab is rare and usually clinically insignificant.1,8
- No studies on statin intolerant patients have evaluated clinical outcomes.9
- Some guidelines recommend considering PCSK9 inhibitors for patients with familial hypercholesterolemia or CVD whose LDL remains above ‘target’ despite maximum-tolerated statin +/- ezetimibe.10,11
- Routine use of PCSK9 inhibitors in CVD patients is not cost-effective at current Canadian prices (~$7,100/year).12 A >90% price reduction would be required for cost-effectiveness.12
Latest Tools for Practice
#379 Bumpin’ Up the Protection? RSV Vaccine in Pregnancy
How effective and safe is the respiratory syncytial virus (RSV) vaccine (AbrysvoTM) when given during pregnancy?
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
